At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
Atezolizumab +3 moredrug
Likely dose
Atezolizumab 1200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Atezolizumab in Combination With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery for Patients With Newly-Diagnosed Advanced-Stage Epithelial Ovarian Cancer
In Brief
A Phase 2 clinical trial evaluating Atezolizumab, Carboplatin, and 2 other interventions for Ovarian Cancer and Ovarian Neoplasms. Completed, enrolled 18 participants across 3 sites.
Detailed Summary
The main purpose of this study is to validate a safe dose of atezolizumab with dose-dense paclitaxel and carboplatin when utilized with neoadjuvant chemotherapy and interval cytoreductive surgery followed by maintenance atezolizumab in women with advanced ovarian cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer, Ovarian Neoplasms
CountriesUnited States
CollaboratorsJohns Hopkins University, Genentech, Inc.
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJan 2018
Enrollment StartJun 2018
Primary CompletionJul 2020
TodayJul 2026
First PostedJan 9, 2018
Enrollment StartJun 19, 2018
Primary CompletionJul 20, 2020
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 8.5 years ago
Interventions
Atezolizumabdrug
1200mg IV q3weeks
Carboplatindrug
5-6mg/ML IV q3 weeks
Paclitaxeldrug
70-80 mg/m2 IV q1 week
Bevacizumabdrug
15 mg/kg IV q3 weeks